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Adrenomedullin, a recently identified potent vasodilator, is ex-
pressed widely and has been suggested to have functions ranging
from reproduction to blood pressure regulation. To elucidate these
functions and define more precisely sites of Adm expression, we
replaced the coding region of the Adm gene in mice with a
sequence encoding enhanced green fluorescent protein while
leaving the Adm promoter intact. We find that Adm2/2 embryos
die at midgestation with extreme hydrops fetalis and cardiovas-
cular abnormalities, including overdeveloped ventricular trabecu-
lae and underdeveloped arterial walls. These data suggest that
genetically determined absence of Adm may be one cause of
nonimmune hydrops fetalis in humans.
Adrenomedullin (Adm), a potent 52-aa peptide vasodilator,was isolated from a human pheochromocytoma on the
basis of its ability to elevate platelet cAMP levels (1). Recently,
Adm has gained much attention in clinical settings because of
its elevated plasma levels in patients with various cardiovas-
cular diseases (2). However, the variety of conditions associ-
ated with elevated Adm levels, which include essential hyper-
tension, septic shock, and normal pregnancy, suggest that
increases in Adm are secondary to other primary events rather
than causative. For example, Adm may be elevated in certain
hypertensive disease states as a compensatory mechanism to
decrease blood pressure, but genetic experiments to distin-
guish between causation and compensation have not yet been
performed.
On the basis of its nucleotide homologies with calcitonin
gene-related peptide (CGRP), calcitonin, and amylin, Adm is
considered to be the fourth CGRP family member. The Adm
gene contains four exons spanning approximately 2 kb and
codes for two biologically active peptides: proadrenomedullin
N-terminal 20 peptide (PAMP) and Adm. Recent studies to
identify the receptors for Adm and CGRP have led to the
discovery of a mechanism of signal transduction whereby a
series of single transmembrane spanning receptor activity-
modifying proteins (RAMPs) interact with a common receptor
to impart specificity of binding for either Adm or CGRP (3).
The differential expression of the receptor activity-modifying
proteins may dictate the sites of function of the two ligands.
To explore the physiological functions of Adm in an in vivo
model, we used homologous recombination in embryonic stem
cells to generate mice that are deficient for the coding region
of the Adm gene. At the same time, to provide a biological
marker for sites of Adm gene expression, we replaced the Adm
coding region with a sequence coding for enhanced green
f luorescent protein (EGFP) while leaving the Adm promoter
and Adm 59 untranslated region intact. Here we show that Adm
is essential for survival because Adm2/2 embryos die at
midgestation with extreme hydrops fetalis. In addition,
Adm2/2 embryos have unusual cardiovascular defects that are
best characterized as overdeveloped ventricular trabeculae
and underdeveloped vascular smooth muscle in the large
arteries. Because the combination of cardiovascular defects
and the severity of hydrops fetalis are, to our knowledge,
unlike any previously described pathology in the mouse, our
data demonstrate a unique role for Adm in development and
suggest that the absence of Adm may be one cause of nonim-
mune hydrops fetalis in humans.
Materials and Methods
Gene Disruption by Homologous Recombination. Mice lacking Adm
were generated with standard gene targeting methods (4). The
targeting construct was made (Fig. 1a) with (i) a 3.7-kb
BamHIySpeI genomic fragment that includes the Adm pro-
moter; (ii) a 600-bp PCR-generated fragment that begins 59
with the endogenous SpeI site, contains exon 1, intron 1, part
of exon 2, and ends 39 at the endogenous initiator methionine;
(iii) a 700-bp cDNA encoding EGFP (CLONTECH); (iv) a
300-bp bovine growth hormone poly(A) addition region; and
(v) a 1.3-kb XhoIySacI genomic fragment from downstream of
the Adm gene. 129-derived SvEv embryonic stem cells (TC-1,
a gift from Phil Leder, Harvard University, Boston, MA) were
electroporated; G418yganciclovir-resistant colonies, initially
identified by the PCR-based assay depicted in Fig. 1 a and c,
were expanded; and homologous recombination was con-
firmed by Southern blot analysis with the use of an 800-bp
SacIyAvr II probe external to the targeting construct sequence
(Fig. 1 a and b). Male chimeras were mated to wild-type SvEv
females to establish an isogenic Adm line, and all experiments
were conducted on the resulting isogenic line.
To generate Adm2/2 embryos, timed heterozygous matings
were set up, and the morning of vaginal plug detection was
considered to be embryonic day 0.5 (E0.5). To genotype the
embryos, DNA was isolated from yolk sac tissue (E8.5–E12.5) or
from a small piece of tail tissue (E12.5–E14.5) and analyzed by
the PCR-based strategy described above.
Expression Analysis by Using Real-Time Quantitative Reverse Tran-
scription–PCR. Expression of the Adm gene was characterized by
real-time quantitative reverse transcription–PCR with the Se-
quence detection system (Perkin–Elmer). Primers for Adm
amplification were 59-GAGCGAAGCCCACATTCGT-39 and
59-GAAGCGGCATCCATTGCT-39. The probe for Adm detec-
tion was 59-FAM-CTACCGCCAGAGCATGAACCAGGG-
Tamra-39. All reactions included a b-actin internal standard. The
primers used for b-actin amplification were 59-CTGCCTG-
ACGGCCAAGTC-39 and 59-CAAGAAGGAAGGCTG-
GAAAAGA-39. The probe for b-actin detection was 59-TET-
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isolated from E9.5 embryos with the use of the TRIzol Reagent
(GIBCOyBRL). The reactions were performed with 5 mg total
RNA with minor differences from ABI 7700 manufacturer’s
instructions. Relative levels of Adm expression were determined
by the DDCt method and expressed as a percentage of wild type
(Fig. 1d). All assays were repeated twice, each with duplicates.
Expression Analysis by Using GFP Fluorescence. Adult or embryonic
heterozygote animals were euthanized, and organs or whole
embryos were fixed in 4% paraformaldehyde. Tissues were
embedded in Tissue-Tek OCT media (Sakura Finetek, Torrance,
CA), and 8-mm frozen sections were analyzed under fluorescent
microscopy. The slides were then stained with hematoxylin/eosin
(H&E) to histologically confirm sites of expression. To visualize
Adm expression during development, heterozygote embryos
were fixed in 4% paraformaldehyde and analyzed by fluorescent
confocal microscopy.
Histological Analysis. Embryos, dissected from the uterus at the
desired gestational times, were fixed in 4% paraformaldehyde,
dehydrated, and embedded in paraffin. Five-micrometer-thick
sections were mounted on slides and stained with H&E.
Results
Targeted disruption of the Adm gene replaced the protein-
coding region of the gene with a cDNA coding for EGFP but left
the 59 regions of the gene intact, so that EGFP expression is Adm
specific (Fig. 1a). The disrupted allele was detected by Southern
blot analysis (Fig. 1b) and by PCR (Fig. 1c). To confirm that the
targeting inactivated the Adm gene, quantitative reverse tran-
scription–PCR was performed on embryonic RNA, with the use
of an Adm TaqMan probe and the ABI7700 Sequence Detection
system. Adm2/2 embryos express Adm mRNA at levels indis-
tinguishable from zero, thus confirming complete loss of Adm
production; heterozygotes have half-normal expression (Fig. 1d).
Mice heterozygous for Adm showed no overt differences from
wild-type mice and were used to determine the pattern of Adm
expression by observing fluorescence from its surrogate, EGFP.
As expected from previous studies (5, 6), the adult adrenal
medulla showed strong fluorescence, but no fluorescence was
detected in the zona fasciculatayreticularis of the adrenal cortex
(Fig. 2a). Confocal microscopy of E9.5 Adm1/2 embryos showed
moderate expression in the heart and strong expression in the
developing vasculature (Fig. 2b). E13.5 Adm1/2 embryos express
Adm in the cardiac myocytes of the developing ventricle (Fig.
2c). The vascular smooth muscle cells of the aorta and esophagus
and the endothelial cells of the aorta and thoracic duct strongly
express Adm (Fig. 2d).
Fig. 1. Generation of Adm2/2 animals by homologous recombination. (a)
Strategy to disrupt the Adm gene. (Top) Endogenous wild-type (WT) allele.
(Middle) Linearized targeting vector. (Bottom) Targeted allele after homol-
ogous recombination. Open boxes represent exons 1–4; the checkered region
in exon 4 codes for the mature Adm peptide; the initiator methionine of the
propeptide is indicated (Met). The solid black box depicts a bovine growth
hormone poly(A) addition sequence downstream of the EGFP cDNA. The
locations of primer sequences for PCR (p1, p2, and p3) are shown by small
arrows. The sequence used as a probe for the Southern-based detection
strategy is indicated by a labeled line (PROBE). Restriction sites: A, AvrII; B,
BamHI; Sc, SacI; Sp, SpeI; X, XhoI. Parentheses denote sites destroyed during
cloning. (b) Detection of the targeted allele by Southern blot analysis.
Genomic DNA from E9.5 embryos was digested with AvrII and probed with the
SacIyAvrII fragment (PROBE) depicted in the bottom line of a. (c) Detection of
the targeted allele by PCR. Genomic DNA from embryos was amplified with
the primer sequences depicted in a. (d) Measurement of Adm RNA in total RNA
extracts from E9.5 embryos by real-time quantitative reverse transcription–
PCR. The relative quantity of Adm RNA in Adm1/2 and Adm2/2 embryos is
expressed as a percentage of total Adm RNA in Adm1/1 embryos. Error bars
represent SEM.
Fig. 2. Sites of Adm expression determined by EGFP fluorescence. (a) Frozen
section of adrenal gland from an adult Adm1/2. Note intense fluorescence in
adrenal medulla (m) and the absence of fluorescence in adrenal cortex (c). (b)
Confocal microscopy of an E9.5 Adm1/2 embryo. Moderate expression is seen
in the heart (arrowhead h), and strong expression in the developing vascula-
ture (arrowhead v) and forebrain (arrowhead b); a speck of nonspecific
fluorescence has been covered with a black box. (c) Frozen section of an E13.5
Adm1/2 embryo, showing expression in the developing left ventricle. Arrow-
heads indicate the pericardial surface of the left ventricle. (d) Frozen section
of an E16.5 Adm1/2 embryo, showing expression in the aorta (a), esophagus
(oe), and thoracic duct (td).
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Mice homozygous for the targeted allele die in utero, as
shown by our finding that among the progeny of Adm1/2 3
Adm1/2 matings 32% were Adm1/1, 68% were Adm1/2, but
none were Adm2/2. Timed matings between Adm1/2 mice
showed that at E12.5 the Adm2/2 embryos are indistinguish-
able from their Adm1/2 and Adm1/1 littermates. However, the
Adm2/2 embryos die between E13.5 and E14.5, as evidenced
by increased numbers of resorbing Adm2/2 embryos (Table 1).
Early in this period, the yolk sac cavity becomes distended
(Fig. 3a), and Adm2/2 embryos exhibit modest general edema
with a notable increase in the size of their thoracic cavities
relative to control littermates (Fig. 3b). By E14.5, Adm2/2
embryos suffer from extreme hydrops fetalis (Fig. 3c) that
encompasses the entire body and neural structures (Fig. 3d).
Note that the yolk sacs have been removed from the embryos
illustrated in Fig. 3 b–d. Histological examination of the
Adm2/2 embryos (Fig. 3f ) confirms the enlargement of their
thoracic cavities and their extreme and generalized hydrops
compared with control littermates (Fig. 3e).
Edema in mice embryos has previously been described in
association with cardiovascular defects, although we find no
reports of edema of this severity (7, 8). We therefore examined
the condition of the heart in transverse sections of E13.5 and
E14.5 Adm2/2 embryos. Fig. 4 illustrates that the E13.5 Adm2/2
heart (Fig. 4d) is typically only two-thirds the size of the
wild-type heart (Fig. 4a) but shows signs of increased left
ventricular trabecular development leading to smaller chamber
size. By E14.5, this pathological overdevelopment becomes more
marked (Fig. 4 b and e): the compact zone appears thin and
convoluted, the number of trabeculae is increased, and the
myocardium has a generally disorganized appearance (Fig. 4 c
and f ). The mitral and tricuspid valves, intraventricular septum,
and atria of Adm2/2 embryos show no obvious abnormalities at
any time.
The aorta and carotid artery of the Adm2/2 embryos are also
abnormal (Fig. 5 c and d); they have markedly thinner walls
and are irregular in shape when compared with wild type (Fig.
5 a and b). However, we observed no significant differences in
the external appearance of the smaller vessels of the paws and
tail (Fig. 2 b and d). The thinner major arteries and the cardiac
pathology of the Adm2/2 embryos demonstrate that cardio-
vascular development is abnormal in the absence of Adm.
Discussion
Because our Adm2/2 animals express EGFP in place of Adm,
we comment on a recent report that extremely high levels of
a GFP transgene expressed in the heart of adult mice causes
dilated cardiomyopathy (9). For several reasons, it is highly
unlikely that the abnormal trabecular development in the
ventricles of our Adm2/2 embryos is caused by EGFP toxicity.
First, the level of EGFP reported to be toxic appears much
greater than in our mice, as judged by f luorescence. Second,
our phenotype manifests itself over 24–48 h during embryonic
development, as opposed to a several-month progression in the
adult transgenic mice. Third, other investigators have previ-
ously shown that GFP is nontoxic in mice (10–12), and that
moderately expressed cardiac-specific GFP transgenes do
not cause adverse effects during embryogenesis or adulthood
(13, 14).
Nonimmune hydrops fetalis has an incidence of 1:3,000 births
and a high fetal mortality rate. One-quarter of these cases are
associated with cardiovascular defects such as arrhythmias and
malformations. Fifteen percent are of unknown etiology. Here




E9.5 37 53 23 113
E10.5 11 15 6 32
E12.5 6 9 5 20
E13.5 11 14 7 32
E14.5 12 30 18* 60
E17.5 4 9 1 14
P10 47 101 0 148
*Dying or resorbed embryos.
Fig. 3. Adm2/2 embryos have massive generalized edema. (a) Appearance of E14.5 Adm2/2 (Left) and Adm1/1 (Right) embryos in their yolk sacs shortly after
dissection from the uterus. Note that the yolk sac (arrowhead ys) of the Adm2/2 embryo is distended with fluid, and its blood vessels are thinner than those of
its wild-type littermate. (b) The thoracic cavity of E13.5 Adm2/2 embryos is considerably enlarged (Left) compared with a wild-type littermate (Right). The black
lines indicate the width of the thoracic cavity just above the diaphragm. (c) Severe hydrops fetalis is apparent in the E14.5 Adm2/2 embryos (Left), readily visible
after their yolk sacs are removed. The arrowheads (s) indicate the outer skin layer of the embryos. (d) The extreme hydrops of the Adm2/2 embryos, dissected
away from their yolk sacs, is completely general, as indicated by the uniformly swollen back and head. The arrowheads (s) again indicate the outer skin layer.
(e and f ) H&E stain of transverse sections through E14.5 Adm1/1 (e) and Adm2/2 ( f) embryos. The Adm2/2 embryo has a fluid-filled thoracic cavity, and the tissues
external to the rib cage are markedly swollen (e and f, 31).











we describe a type of nonimmune hydrops fetalis that is asso-
ciated with cardiovascular defects and is caused by a single gene
defect. Cardiovascular defects have been reported in mice having
a wide variety of disrupted genes [RXR a (8, 15), a 4 integrin
(16), PDGF a (17), BARK 1 (18), Hand-1 (19, 20), PPAR g (21),
calreticulin (22), jumonji (23), etc.] likely reflecting the many
ways in which cardiac anomalies can be induced. However, the
consequences of these gene deficiencies differ in two fundamen-
tal ways from the Adm2/2 phenotype. First, any observed edema
tends to be mild, localized, and subcutaneous. Second, the heart
defects are generally characterized as involving hypoplasia in-
dicative of impaired myocardial growth and subsequent ventric-
ular dilation. In contrast, Adm2/2 hearts show evidence of
trabecular hyperplasia that can progress sufficiently to cause
ventricular occlusion. Adm, secreted by neonatal rat cardiomy-
ocytes, inhibits protein synthesis and collagen production when
it is added to cultured cardiomyocytes (24) or cardiac fibroblasts
(25). In line with these findings, our observations suggest that
absence of Adm in the developing heart leads to abnormally
enhanced growth. However, in apparent contrast, our studies
also show that the absence of Adm results in less than normal
vascular smooth muscle cell development in large arteries, which
is unlikely to be secondary to low blood pressure caused by a
poorly functioning heart because it does not occur in other mice
with cardiac failure.
The extreme hydrops of Adm2/2 embryos requires comment. For
the above reasons, it is unlikely to be solely because of cardiac or
vascular defects. Likewise, it is unlikely that abnormal vascular
permeability could account for the hydrops, because gene disrup-
tion models with vascular permeability defects do not show the
same degree of edema (26–28). Abnormalities in lymphatic vessel
development could theoretically cause the severe edema, and
lymphatic vessels sprout from veins around E12.5 in mice, which is
the time of the hydrops onset in our mutants. Furthermore, we find
that Adm is expressed in the thoracic duct of Adm1/2 embryos (Fig.
2d). However, current data are not yet sufficient to allow a chain of
events to be specified that leads to the hydrops of Adm2/2 embryos.
Nevertheless, our overall data suggest that a genetically determined
absence of Adm could be one cause of nonimmune hydrops fetalis
in humans.
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Fig. 4. Adm2/2 embryos have developmental heart defects. Transverse sections through the hearts of Adm1/1 (Upper) and Adm2/2 (Lower) embryos were
stained with H&E. (a) E13.5 Adm1/1 littermate. (d) E13.5 Adm2/2 embryo. The heart of the Adm2/2 embryo is smaller than the heart of its wild-type littermate.
(b) E14.5 Adm1/1 littermate. (e) E14.5 Adm2/2 embryo. The heart of the Adm2/2 embryo is still smaller, and the left ventricle is significantly occluded with
increased trabeculae compared with its Adm1/1 littermate. (c) E14.5 Adm1/1 littermate. ( f) E14.5 Adm2/2 embryo. Higher-power magnification of the left
ventricle at E14.5 shows an increase in the number of trabeculae, a thinner, convoluted compact zone (cz), and a generally delaminated appearance of the
Adm2/2 heart compared with wild type. c, endocardial cushion; s, septum; t, tricuspid valve; m, mitral valve; rv, right ventricle; lv, left ventricle; ch, chamber; cz,
compact zone (a, b, d, and e, 32; c and f, 310).
Fig. 5. Adm2/2 embryos have thin arterial walls. Transverse sections
through vessels of Adm1/1 (Upper) and Adm2/2 (Lower) embryos at E13.5
were stained with H&E. (a and c) aorta; (b and d) carotid artery. Note the
thin vascular walls (approximately three cells thick) of the Adm2/2 vessels
compared with wild-type vessels (approximately five cells thick). a, aorta;
c, carotid artery (310).
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